Biocon is a biopharmaceutical company focused on discovery, development, manufacturing and commercialization of biotechnology-based therapies. It operates across four segments: Biosimilars, Generics, Novel Biologics and Research Services. The company develops insulin products, monoclonal antibodies and other therapeutic proteins, including biosimilars, aimed at diabetes, oncology, immunology and autoimmune diseases. Through its subsidiary Syngene, Biocon provides integrated contract research and manufacturing services to the pharma industry. The group maintains substantial manufacturing capacity and serves markets in India and abroad, including the United States and Europe. A key subsidiary, Biocon Biologics, specializes in biosimilars and complex biologics, developing and commercializing a differentiated portfolio of biosimilars, novel biologics and APIs for global markets. The company emphasizes expanding patient access to affordable biologic therapies through its biosimilars and cost-effective development capabilities.
Viatris Biosimilars is focused on the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology.
Fusion Microfinance
Series D in 2016
Founded in New Delhi in 2010, Fusion Microfinance operates primarily in North Central India. It specializes in providing microloans to women organized into Joint Liability Groups (JLGs), empowering them with financial services. Additionally, the company offers loans to small and medium enterprises (MSMEs) and facilitates access to other financial products like mobile handsets and bicycles through its distribution network.
Glympse Bio
Seed Round in 2015
Glympse Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing modular nanoparticle sensors for noninvasive diagnostics. Founded in 2015, the company focuses on creating diagnostic solutions for various diseases, including fibrosis, cancer, immunology, and infectious diseases. Utilizing a unique platform technology originally developed at MIT, Glympse Bio employs precisely engineered diagnostic agents that interrogate the body to detect specific disease states and transmit this information to urine for analysis. This innovative approach facilitates predictive monitoring and enhances the ability of physicians to assess treatment responses accurately. The company aims to transform disease monitoring and improve patient outcomes through its Glympse Inside product engine, which supports comprehensive, pan-disease diagnostics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.